SCHEMBL24848943

SCHEMBL24848943

COC(=O)c1cc(C=O)ncc1Nc1ccc(S(C)(C)C)cc1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 3/20 0.34
▸ CSF1R P07333 3/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ TGFBR1 P36897 1/20 0.32
▸ NUDT1 P36639 4/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ YAP1 P46937 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24849394 0.85 DHODH (0.36) DHODHCSF1RCA1CA2CA9
SCHEMBL24849417 0.84 KDM4E (0.42) DHODHCA1CA2CA9MAPK1
SCHEMBL29781364 0.83 MAPK14 (0.34) DHODHCSF1RTGFBR1NUDT1LMNA
SCHEMBL29425398 0.83 MAPK14 (0.34) DHODHCSF1RTGFBR1NUDT1LMNA
SCHEMBL23673897 0.83 MAPK14 (0.34) DHODHCSF1RTGFBR1NUDT1LMNA
SCHEMBL24848964 0.83 DHODH (0.36) DHODHCSF1RCA1CA2CA9
SCHEMBL24849669 0.82 DHODH (0.36) DHODHCSF1RCA1CA2CA9
SCHEMBL24849644 0.74 NUDT1 (0.33) DHODHCSF1RCA1CA2TGFBR1
SCHEMBL24196100 0.71 KEAP1 (0.36) CSF1RCA1CA2CA9NUDT1
SCHEMBL24195914 0.71 LMNA (0.38) CA1CA2CA9LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-31 — — US disclosed
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE BRAF, NRAS, KRAS DHODH 2249/4885CSF1R 1365/4885CA1 4751/4885
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, NRAS, KRAS DHODH 3092/4885CSF1R 1142/4885CA1 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback